影响因子(Impact Factor, IF)是衡量学术期刊影响力的国际通行指标。它是由科睿唯安(Clarivate Analytics)公司根据Web of Science数据库中的数据计算得出的。具体计算公式为:某年影响因子 = 该年期刊被引用的次数 / 该年期刊发表的论文篇数。影响因子越高,说明期刊的学术影响力越大。这...
2023 年11 月,美国 FDA 批准了由中国制药企业和黄医药开发的首个治疗转移性结直肠癌的小分子抗癌药物 Fruquintinib。2023 年,BioGene 公司开发的BTK 抑制剂 Zanubrutinib 全球销售额超过 10 亿美元,用于治疗既往接受过治疗的成人袍状细胞淋巴瘤。由真实生物、先声...
JMC要分为A,B,C了 都是从2013年开始 那明年JMC还有没有影响因子啊？[Last edited by cxksama on ...
Unfortunately, Journal of Materials Chemistry has been omitted from the list and we are contacting Thomson Reuters to correct this. We were told when we were looking into the journal division that the parent journal would continue to receive an impact factor until the 2014 JCR (to be released ...
Editor-in-Chief Craig W. Lindsley Vanderbilt University Medical Center The Journal of Medicinal Chemistry发表分子结构与生物活性或作用模式之间关系的相关研究。 2-Year Impact Factor CiteScore Time to First Peer Review Decision 6.8 12.8 28.1
We probably need to either (a) get the R language pack to do its discovery even in untrusted workspaces, or (b) make sure a discovery pass happens after workspace trust is granted (either a second pass or moving the first pass). announce limited support for untrusted workspaces 15d0efb ...
[6]Passamonti, L., Rowe, J. B., Schwarzbauer, C., Ewbank, M. P., Von Dem Hagen, E., & Calder, A. J. (2009). Personality predicts the brain's response to viewing appetizing foods: the neural basis of a risk factor for overeating. Journal of Neuroscience, 29(1), 43-51. ...
Need units, not # Wrong date format Missing date Inconsistent with each other Missing Data Case #VHUP # dog name WBC Temp 13 699495 Champ Day 1 0.71 104 3 mos mixb Day 2 0.73 Day 3 1.19 101 Day 4 5.82 101 18 699721 Killer Day 1 0.17 103 Day 2 1.46 103 Day 3 5.75 103 Day 4...
Abhishek Keshav Sharan Saxena, A.B. Soni, Anandkumar Jayapal September 2024 Pages 210-220 select article Optimization of ultrasound-assisted extraction of phenolics from <em>Cordia dichotoma</em> leaves using response surface methodology Research articleAbstract only ...
The combination or "cocktail" antibody regimes of JS016 and LY-CoV555, also known as bamlanivimab, has shown effectiveness in reducing the risk of COVID-19 hospitalizations and death by 70 percent, according to its phase II and phase III trial data. ...